UK-based Vernalis saw its share price plunge as much as 20% after the company reported top-line results of the 162-patient IN-STEP Phase IIb trial of indantandol in diabetic neuropathic pain (DNP) which indicated that a high placebo response rate caused the primary endpoint of change in pain score from baseline to be missed.
An earlier Phase IIa study in this indication gave mixed results due to high placebo responders which led Vernalis to design INSTEP with a two-week placebo run-in period in an attempt to eliminate this effect. Of the 271 patients enrolled in IN-STEP, 162 went on to enrol in the 13-week, double-blind, placebo-controlled treatment phase of placebo or up to 400mg indantadol taken twice a day.
While the full analysis of the IN-STEP dataset is ongoing, it is unlikely that Vernalis will carry out further studies of indantadol in DNP (historically a high-risk indication from a development perspective); the failure of this trial has also removed a potential near-term partnering catalyst, comment analyst Robin Davidson at Edison Equity Research.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze